Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Emory University Juvenile Diabetes Research Foundation |
---|---|
Information provided by: | Emory University |
ClinicalTrials.gov Identifier: | NCT00276250 |
Islet transplantation in type 1 diabetics with hypoglycemic unawareness using abatacept as a part of a novel calcineurin-inhibitor-sparing immunosuppressive regimen.
Condition | Intervention | Phase |
---|---|---|
Type 1 Diabetes Mellitus |
Drug: Human Islets Drug: abatacept |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Development of Immunosuppression Regimens to Facilitate Single Donor Islet Transplantation Using Abatacept |
Estimated Enrollment: | 20 |
Study Start Date: | December 2005 |
Estimated Study Completion Date: | December 2010 |
Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
islet transplant, all participants: Experimental |
Drug: Human Islets
final dosage is according to participant's weight and yield from islet isolation. up to 3 transplants per participant.
Drug: abatacept
monthly, weight-dosed, intravenous abatacept infusions, given for as long as transplanted islets are functioning
|
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Active alcohol abuse should be considered using the current NIAAA definitions, whereby alcohol abuse is defined by a pattern of drinking that is accompanied by one or more of the following situations within a 12-month period:
United States, Georgia | |
Emory University | |
Atlanta, Georgia, United States, 30322 |
Principal Investigator: | Christian P Larsen, MD, D.Phil | Emory University |
Principal Investigator: | Thomas C Pearson, MD, D,Phil | Emory University |
Study Director: | Jennifer Hutchinson, RN, MS | Emory University |
Principal Investigator: | Nicole Turgeon, MD | Emory University |
Responsible Party: | Emory University ( Christian P. Larsen, MD, DPhil ) |
Study ID Numbers: | 1136-2005 |
Study First Received: | January 12, 2006 |
Last Updated: | July 21, 2009 |
ClinicalTrials.gov Identifier: | NCT00276250 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Metabolic Diseases Autoimmune Diseases Immunologic Factors Diabetes Mellitus Endocrine System Diseases Diabetes Mellitus Type 1 Immunosuppressive Agents |
Abatacept Diabetes Mellitus, Type 1 Endocrinopathy Glucose Metabolism Disorders Antirheumatic Agents Metabolic Disorder |
Metabolic Diseases Autoimmune Diseases Immune System Diseases Immunologic Factors Physiological Effects of Drugs Diabetes Mellitus Endocrine System Diseases |
Immunosuppressive Agents Pharmacologic Actions Abatacept Diabetes Mellitus, Type 1 Therapeutic Uses Glucose Metabolism Disorders Antirheumatic Agents |